Home

Download

Statistics

Examples

Help

Contact

Fusion Protein:GGT6-PELP1

Fusion Gene and Fusion Protein Summary

Fusion gene summary

Fusion partner gene information	Fusion gene name: GGT6-PELP1
	FusionPDB ID: 33046
	FusionGDB2.0 ID: 33046
		Hgene	Tgene
	Gene symbol	GGT6	PELP1
	Gene ID	124975	27043
	Gene name	gamma-glutamyltransferase 6	proline, glutamate and leucine rich protein 1
	Synonyms	-	MNAR\|P160
	Cytomap	17p13.2	17p13.2
	Type of gene	protein-coding	protein-coding
	Description	glutathione hydrolase 6gamma-glutamyltransferase 6 homologgamma-glutamyltranspeptidase 6	proline-, glutamic acid- and leucine-rich protein 1modulator of non-genomic activity of estrogen receptorproline and glutamic acid rich nuclear proteintranscription factor HMX3
	Modification date	20200313	20200329
	UniProtAcc	Q6P531 Main function of 5'-partner protein: FUNCTION: Cleaves glutathione conjugates. {ECO:0000250}.	.
Ensembl transtripts involved in fusion gene	ENST ids	ENST00000301395, ENST00000381550, ENST00000574154, ENST00000573591,	ENST00000570823, ENST00000269230, ENST00000301396, ENST00000436683, ENST00000572293, ENST00000574876,
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)	* DoF score	1 X 2 X 1=2	7 X 5 X 7=245
	# samples	2	13
	** MAII score	log2(2/2*10)=3.32192809488736	log2(13/245*10)=-0.914270125974116 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0
Fusion gene context	PubMed: GGT6 [Title/Abstract] AND PELP1 [Title/Abstract] AND fusion [Title/Abstract]
Fusion neoantigen context	PubMed: GGT6 [Title/Abstract] AND PELP1 [Title/Abstract] AND neoantigen [Title/Abstract]
Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)	GGT6(4463677)-PELP1(4580107), # samples:2
Anticipated loss of major functional domain due to fusion event.	GGT6-PELP1 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. GGT6-PELP1 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. GGT6-PELP1 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. GGT6-PELP1 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.

* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez

Partner	Gene	GO ID	GO term	PubMed ID
Tgene	PELP1	GO:0045944	positive regulation of transcription by RNA polymerase II	17505058
Tgene	PELP1	GO:0071391	cellular response to estrogen stimulus	17505058

Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr17:4463677/chr17:4580107)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.

Retention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

Fusion gene breakpoints across GGT6 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Fusion gene breakpoints across PELP1 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Top

Fusion Amino Acid Sequences

Fusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	Seq length (transcript)	BP loci (transcript)	Predicted start (transcript)	Predicted stop (transcript)	Seq length (amino acids)
ENST00000301395	GGT6	chr17	4463677	-	ENST00000574876	PELP1	chr17	4580107	-	3006	200	2	2950	982
ENST00000301395	GGT6	chr17	4463677	-	ENST00000572293	PELP1	chr17	4580107	-	3005	200	2	2950	982
ENST00000301395	GGT6	chr17	4463677	-	ENST00000269230	PELP1	chr17	4580107	-	2735	200	2	2680	892
ENST00000301395	GGT6	chr17	4463677	-	ENST00000301396	PELP1	chr17	4580107	-	3437	200	2	3382	1126
ENST00000301395	GGT6	chr17	4463677	-	ENST00000436683	PELP1	chr17	4580107	-	2743	200	2	2719	905
ENST00000574154	GGT6	chr17	4463677	-	ENST00000574876	PELP1	chr17	4580107	-	3243	437	50	3187	1045
ENST00000574154	GGT6	chr17	4463677	-	ENST00000572293	PELP1	chr17	4580107	-	3242	437	50	3187	1045
ENST00000574154	GGT6	chr17	4463677	-	ENST00000269230	PELP1	chr17	4580107	-	2972	437	50	2917	955
ENST00000574154	GGT6	chr17	4463677	-	ENST00000301396	PELP1	chr17	4580107	-	3674	437	50	3619	1189
ENST00000574154	GGT6	chr17	4463677	-	ENST00000436683	PELP1	chr17	4580107	-	2980	437	50	2956	968
ENST00000381550	GGT6	chr17	4463677	-	ENST00000574876	PELP1	chr17	4580107	-	3001	195	33	2945	970
ENST00000381550	GGT6	chr17	4463677	-	ENST00000572293	PELP1	chr17	4580107	-	3000	195	33	2945	970
ENST00000381550	GGT6	chr17	4463677	-	ENST00000269230	PELP1	chr17	4580107	-	2730	195	33	2675	880
ENST00000381550	GGT6	chr17	4463677	-	ENST00000301396	PELP1	chr17	4580107	-	3432	195	33	3377	1114
ENST00000381550	GGT6	chr17	4463677	-	ENST00000436683	PELP1	chr17	4580107	-	2738	195	33	2714	893
ENST00000301395	GGT6	chr17	4463676	-	ENST00000574876	PELP1	chr17	4580107	-	3006	200	2	2950	982
ENST00000301395	GGT6	chr17	4463676	-	ENST00000572293	PELP1	chr17	4580107	-	3005	200	2	2950	982
ENST00000301395	GGT6	chr17	4463676	-	ENST00000269230	PELP1	chr17	4580107	-	2735	200	2	2680	892
ENST00000301395	GGT6	chr17	4463676	-	ENST00000301396	PELP1	chr17	4580107	-	3437	200	2	3382	1126
ENST00000301395	GGT6	chr17	4463676	-	ENST00000436683	PELP1	chr17	4580107	-	2743	200	2	2719	905
ENST00000574154	GGT6	chr17	4463676	-	ENST00000574876	PELP1	chr17	4580107	-	3243	437	50	3187	1045
ENST00000574154	GGT6	chr17	4463676	-	ENST00000572293	PELP1	chr17	4580107	-	3242	437	50	3187	1045
ENST00000574154	GGT6	chr17	4463676	-	ENST00000269230	PELP1	chr17	4580107	-	2972	437	50	2917	955
ENST00000574154	GGT6	chr17	4463676	-	ENST00000301396	PELP1	chr17	4580107	-	3674	437	50	3619	1189
ENST00000574154	GGT6	chr17	4463676	-	ENST00000436683	PELP1	chr17	4580107	-	2980	437	50	2956	968
ENST00000381550	GGT6	chr17	4463676	-	ENST00000574876	PELP1	chr17	4580107	-	3001	195	33	2945	970
ENST00000381550	GGT6	chr17	4463676	-	ENST00000572293	PELP1	chr17	4580107	-	3000	195	33	2945	970
ENST00000381550	GGT6	chr17	4463676	-	ENST00000269230	PELP1	chr17	4580107	-	2730	195	33	2675	880
ENST00000381550	GGT6	chr17	4463676	-	ENST00000301396	PELP1	chr17	4580107	-	3432	195	33	3377	1114
ENST00000381550	GGT6	chr17	4463676	-	ENST00000436683	PELP1	chr17	4580107	-	2738	195	33	2714	893

DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	No-coding score	Coding score
ENST00000301395	ENST00000574876	GGT6	chr17	4463677	-	PELP1	chr17	4580107	-	0.016350893	0.98364913
ENST00000301395	ENST00000572293	GGT6	chr17	4463677	-	PELP1	chr17	4580107	-	0.016304925	0.98369503
ENST00000301395	ENST00000269230	GGT6	chr17	4463677	-	PELP1	chr17	4580107	-	0.01900988	0.98099005
ENST00000301395	ENST00000301396	GGT6	chr17	4463677	-	PELP1	chr17	4580107	-	0.004674567	0.99532545
ENST00000301395	ENST00000436683	GGT6	chr17	4463677	-	PELP1	chr17	4580107	-	0.020677052	0.9793229
ENST00000574154	ENST00000574876	GGT6	chr17	4463677	-	PELP1	chr17	4580107	-	0.017287163	0.98271286
ENST00000574154	ENST00000572293	GGT6	chr17	4463677	-	PELP1	chr17	4580107	-	0.017237598	0.9827624
ENST00000574154	ENST00000269230	GGT6	chr17	4463677	-	PELP1	chr17	4580107	-	0.018081749	0.9819182
ENST00000574154	ENST00000301396	GGT6	chr17	4463677	-	PELP1	chr17	4580107	-	0.005842257	0.9941578
ENST00000574154	ENST00000436683	GGT6	chr17	4463677	-	PELP1	chr17	4580107	-	0.02267043	0.97732955
ENST00000381550	ENST00000574876	GGT6	chr17	4463677	-	PELP1	chr17	4580107	-	0.016335836	0.98366416
ENST00000381550	ENST00000572293	GGT6	chr17	4463677	-	PELP1	chr17	4580107	-	0.016295522	0.9837045
ENST00000381550	ENST00000269230	GGT6	chr17	4463677	-	PELP1	chr17	4580107	-	0.019096255	0.9809037
ENST00000381550	ENST00000301396	GGT6	chr17	4463677	-	PELP1	chr17	4580107	-	0.004650201	0.99534976
ENST00000381550	ENST00000436683	GGT6	chr17	4463677	-	PELP1	chr17	4580107	-	0.020675942	0.9793241
ENST00000301395	ENST00000574876	GGT6	chr17	4463676	-	PELP1	chr17	4580107	-	0.016350893	0.98364913
ENST00000301395	ENST00000572293	GGT6	chr17	4463676	-	PELP1	chr17	4580107	-	0.016304925	0.98369503
ENST00000301395	ENST00000269230	GGT6	chr17	4463676	-	PELP1	chr17	4580107	-	0.01900988	0.98099005
ENST00000301395	ENST00000301396	GGT6	chr17	4463676	-	PELP1	chr17	4580107	-	0.004674567	0.99532545
ENST00000301395	ENST00000436683	GGT6	chr17	4463676	-	PELP1	chr17	4580107	-	0.020677052	0.9793229
ENST00000574154	ENST00000574876	GGT6	chr17	4463676	-	PELP1	chr17	4580107	-	0.017287163	0.98271286
ENST00000574154	ENST00000572293	GGT6	chr17	4463676	-	PELP1	chr17	4580107	-	0.017237598	0.9827624
ENST00000574154	ENST00000269230	GGT6	chr17	4463676	-	PELP1	chr17	4580107	-	0.018081749	0.9819182
ENST00000574154	ENST00000301396	GGT6	chr17	4463676	-	PELP1	chr17	4580107	-	0.005842257	0.9941578
ENST00000574154	ENST00000436683	GGT6	chr17	4463676	-	PELP1	chr17	4580107	-	0.02267043	0.97732955
ENST00000381550	ENST00000574876	GGT6	chr17	4463676	-	PELP1	chr17	4580107	-	0.016335836	0.98366416
ENST00000381550	ENST00000572293	GGT6	chr17	4463676	-	PELP1	chr17	4580107	-	0.016295522	0.9837045
ENST00000381550	ENST00000269230	GGT6	chr17	4463676	-	PELP1	chr17	4580107	-	0.019096255	0.9809037
ENST00000381550	ENST00000301396	GGT6	chr17	4463676	-	PELP1	chr17	4580107	-	0.004650201	0.99534976
ENST00000381550	ENST00000436683	GGT6	chr17	4463676	-	PELP1	chr17	4580107	-	0.020675942	0.9793241

Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for GGT6-PELP1

+/-13 AA sequence from the breakpoints of the fusion protein sequences.

Hgene	Hchr	Hbp	Tgene	Tchr	Tbp	Length(fusion protein)	BP in fusion protein	Peptide
GGT6	chr17	4463676	PELP1	chr17	4580107	195	509	PSPFRAPPFHPPGPMPSVGSMPSAGP
GGT6	chr17	4463676	PELP1	chr17	4580107	195	53	GAGSKPPEAPGLFQGKLASFFLSRVD
GGT6	chr17	4463676	PELP1	chr17	4580107	195	653	PSPFRAPPFHPPGPMPSVGSMPSAGP
GGT6	chr17	4463676	PELP1	chr17	4580107	200	521	PSPFRAPPFHPPGPMPSVGSMPSAGP
GGT6	chr17	4463676	PELP1	chr17	4580107	200	65	GAGSKPPEAPGLFQGKLASFFLSRVD
GGT6	chr17	4463676	PELP1	chr17	4580107	200	665	PSPFRAPPFHPPGPMPSVGSMPSAGP
GGT6	chr17	4463676	PELP1	chr17	4580107	437	128	GAGSKPPEAPGLFQGKLASFFLSRVD
GGT6	chr17	4463676	PELP1	chr17	4580107	437	584	PSPFRAPPFHPPGPMPSVGSMPSAGP
GGT6	chr17	4463676	PELP1	chr17	4580107	437	728	PSPFRAPPFHPPGPMPSVGSMPSAGP
GGT6	chr17	4463677	PELP1	chr17	4580107	195	509	PSPFRAPPFHPPGPMPSVGSMPSAGP
GGT6	chr17	4463677	PELP1	chr17	4580107	195	53	GAGSKPPEAPGLFQGKLASFFLSRVD
GGT6	chr17	4463677	PELP1	chr17	4580107	195	653	PSPFRAPPFHPPGPMPSVGSMPSAGP
GGT6	chr17	4463677	PELP1	chr17	4580107	200	521	PSPFRAPPFHPPGPMPSVGSMPSAGP
GGT6	chr17	4463677	PELP1	chr17	4580107	200	65	GAGSKPPEAPGLFQGKLASFFLSRVD
GGT6	chr17	4463677	PELP1	chr17	4580107	200	665	PSPFRAPPFHPPGPMPSVGSMPSAGP
GGT6	chr17	4463677	PELP1	chr17	4580107	437	128	GAGSKPPEAPGLFQGKLASFFLSRVD
GGT6	chr17	4463677	PELP1	chr17	4580107	437	584	PSPFRAPPFHPPGPMPSVGSMPSAGP
GGT6	chr17	4463677	PELP1	chr17	4580107	437	728	PSPFRAPPFHPPGPMPSVGSMPSAGP

Top

Potential FusionNeoAntigen Information of GGT6-PELP1 in HLA I

Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.

GGT6-PELP1_4463676_4580107.msa

Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)

Fusion gene	Hchr	Hbp	Tgene	Tchr	Tbp	HLA I	FusionNeoAntigen peptide	Binding score	Immunogenic score	Neoantigen start (at BP 13)	Neoantigen end (at BP 13)
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B07:02	GPMPSVGSM	0.999	0.5227	12	21
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B07:05	GPMPSVGSM	0.999	0.6065	12	21
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B07:10	GPMPSVGSM	0.9989	0.5683	12	21
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B15:01	FQGKLASFF	0.9964	0.9447	12	21
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B39:06	FHPPGPMPS	0.9958	0.9174	8	17
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B56:01	HPPGPMPSV	0.9957	0.5339	9	18
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B07:05	APGLFQGKL	0.9919	0.5465	8	17
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B07:05	HPPGPMPSV	0.9897	0.591	9	18
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B07:10	HPPGPMPSV	0.9891	0.5278	9	18
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B35:02	HPPGPMPSV	0.984	0.898	9	18
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B35:04	HPPGPMPSV	0.984	0.898	9	18
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B35:01	GPMPSVGSM	0.9825	0.8546	12	21
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B51:01	HPPGPMPSV	0.9819	0.5325	9	18
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B35:03	HPPGPMPSV	0.9809	0.714	9	18
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B35:08	GPMPSVGSM	0.976	0.8403	12	21
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B35:03	GPMPSVGSM	0.9624	0.8725	12	21
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B35:05	HPPGPMPSV	0.9196	0.6247	9	18
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B35:05	GPMPSVGSM	0.8857	0.7595	12	21
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B15:25	FQGKLASFF	0.8576	0.9681	12	21
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-A24:14	LFQGKLASF	0.8122	0.6726	11	20
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B35:04	GPMPSVGSM	0.7938	0.9693	12	21
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B35:02	GPMPSVGSM	0.7938	0.9693	12	21
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B15:03	FQGKLASFF	0.6372	0.86	12	21
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B08:09	HPPGPMPSV	0.5971	0.8642	9	18
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B82:01	HPPGPMPSV	0.3749	0.5633	9	18
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B81:01	HPPGPMPSV	0.3422	0.7648	9	18
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B13:01	FQGKLASFF	0.245	0.9907	12	21
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B81:01	GPMPSVGSM	0.1818	0.905	12	21
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B82:01	GPMPSVGSM	0.0713	0.709	12	21
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B82:01	APGLFQGKL	0.0342	0.8802	8	17
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B81:01	APGLFQGKL	0.0185	0.7945	8	17
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B15:01	GLFQGKLASF	0.9999	0.903	10	20
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B39:24	FHPPGPMPSV	0.9992	0.9235	8	18
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B39:06	FHPPGPMPSV	0.9992	0.9545	8	18
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B39:01	FHPPGPMPSV	0.9983	0.9789	8	18
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B07:05	APPFHPPGPM	0.9978	0.6346	5	15
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B07:02	APPFHPPGPM	0.9977	0.619	5	15
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B38:01	FHPPGPMPSV	0.9966	0.9905	8	18
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B15:10	FHPPGPMPSV	0.9863	0.6701	8	18
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B15:25	GLFQGKLASF	0.9855	0.9265	10	20
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B51:02	FHPPGPMPSV	0.9624	0.696	8	18
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B15:37	FHPPGPMPSV	0.9237	0.6878	8	18
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B51:01	FHPPGPMPSV	0.9054	0.7958	8	18
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B81:01	APPFHPPGPM	0.7884	0.7331	5	15
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B13:01	GLFQGKLASF	0.6162	0.9932	10	20
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B82:01	APPFHPPGPM	0.5814	0.7072	5	15
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B07:02	RAPPFHPPGPM	0.9995	0.7556	4	15
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B07:05	RAPPFHPPGPM	0.9995	0.7168	4	15
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B81:01	RAPPFHPPGPM	0.9779	0.6546	4	15
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B54:01	HPPGPMPSV	0.9964	0.8382	9	18
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B07:12	GPMPSVGSM	0.992	0.6758	12	21
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B78:01	HPPGPMPSV	0.991	0.6635	9	18
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B35:12	HPPGPMPSV	0.984	0.898	9	18
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B51:07	HPPGPMPSV	0.9796	0.9703	9	18
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B56:04	HPPGPMPSV	0.9662	0.7437	9	18
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B15:07	FQGKLASFF	0.9639	0.8449	12	21
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B15:21	LFQGKLASF	0.9544	0.9383	11	20
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B56:04	GPMPSVGSM	0.8517	0.6312	12	21
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B07:04	GPMPSVGSM	0.8355	0.5735	12	21
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B07:12	HPPGPMPSV	0.8266	0.5752	9	18
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B07:12	APGLFQGKL	0.8174	0.6068	8	17
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B07:12	PPFHPPGPM	0.8065	0.5335	6	15
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B35:12	GPMPSVGSM	0.7938	0.9693	12	21
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B42:02	HPPGPMPSV	0.767	0.7347	9	18
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B42:01	HPPGPMPSV	0.7303	0.7308	9	18
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B39:10	GPMPSVGSM	0.6953	0.9792	12	21
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-C07:10	LFQGKLASF	0.6778	0.9706	11	20
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B15:05	FQGKLASFF	0.646	0.9606	12	21
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B39:10	HPPGPMPSV	0.6243	0.9338	9	18
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B39:09	HPPGPMPSV	0.6242	0.8615	9	18
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B42:02	GPMPSVGSM	0.4467	0.9009	12	21
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B42:01	GPMPSVGSM	0.3358	0.8965	12	21
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B78:01	GPMPSVGSM	0.3253	0.9292	12	21
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-C01:30	HPPGPMPSV	0.3017	0.9649	9	18
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B42:02	APGLFQGKL	0.1971	0.9316	8	17
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B42:01	APGLFQGKL	0.1799	0.9283	8	17
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-C01:17	HPPGPMPSV	0.1641	0.9595	9	18
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-C04:07	HPPGPMPSV	0.0089	0.9753	9	18
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B15:07	GLFQGKLASF	0.9998	0.8445	10	20
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B15:04	GLFQGKLASF	0.9995	0.93	10	20
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B39:09	FHPPGPMPSV	0.9981	0.9474	8	18
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B54:01	FHPPGPMPSV	0.9965	0.9179	8	18
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B39:05	FHPPGPMPSV	0.996	0.9758	8	18
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B07:12	APPFHPPGPM	0.9947	0.6691	5	15
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B07:04	APPFHPPGPM	0.9665	0.632	5	15
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B78:01	FHPPGPMPSV	0.9398	0.8846	8	18
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-C07:13	FHPPGPMPSV	0.9085	0.9628	8	18
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B15:05	GLFQGKLASF	0.8982	0.9495	10	20
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-C07:29	FHPPGPMPSV	0.8931	0.9436	8	18
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B42:01	APPFHPPGPM	0.8536	0.8284	5	15
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B51:08	FHPPGPMPSV	0.7927	0.6515	8	18
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B56:04	APPFHPPGPM	0.6612	0.748	5	15
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B15:07	GLFQGKLASFF	0.9998	0.9066	10	21
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B73:01	FRAPPFHPPGP	0.9996	0.8995	3	14
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B07:12	RAPPFHPPGPM	0.9989	0.8212	4	15
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-C01:17	RAPPFHPPGPM	0.9988	0.9702	4	15
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B07:04	RAPPFHPPGPM	0.9979	0.7512	4	15
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-C01:30	RAPPFHPPGPM	0.9974	0.9653	4	15
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B07:09	GPMPSVGSM	0.999	0.5805	12	21
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B07:22	GPMPSVGSM	0.999	0.5227	12	21
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B15:33	FQGKLASFF	0.9964	0.9447	12	21
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B15:125	FQGKLASFF	0.9964	0.9447	12	21
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B15:34	FQGKLASFF	0.9964	0.9447	12	21
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B15:27	FQGKLASFF	0.9962	0.944	12	21
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B35:22	HPPGPMPSV	0.996	0.6709	9	18
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B15:135	FQGKLASFF	0.9959	0.9481	12	21
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B15:50	FQGKLASFF	0.9941	0.9653	12	21
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B15:24	FQGKLASFF	0.9922	0.95	12	21
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B56:05	HPPGPMPSV	0.9922	0.5685	9	18
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B55:02	HPPGPMPSV	0.9875	0.645	9	18
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B07:09	HPPGPMPSV	0.9862	0.5301	9	18
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B35:09	HPPGPMPSV	0.984	0.898	9	18
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B78:02	HPPGPMPSV	0.9833	0.8131	9	18
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B51:13	HPPGPMPSV	0.9829	0.6913	9	18
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B35:77	GPMPSVGSM	0.9825	0.8546	12	21
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B51:21	HPPGPMPSV	0.9814	0.6021	9	18
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B35:23	GPMPSVGSM	0.9806	0.867	12	21
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B35:13	HPPGPMPSV	0.9781	0.723	9	18
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B59:01	HPPGPMPSV	0.9755	0.6804	9	18
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B51:14	HPPGPMPSV	0.9703	0.5172	9	18
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B56:02	HPPGPMPSV	0.9662	0.7437	9	18
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B15:12	FQGKLASFF	0.9655	0.9257	12	21
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B15:35	FQGKLASFF	0.962	0.9291	12	21
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B35:13	GPMPSVGSM	0.9521	0.8788	12	21
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B35:11	GPMPSVGSM	0.9409	0.9185	12	21
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B55:04	HPPGPMPSV	0.9376	0.7464	9	18
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B15:53	FQGKLASFF	0.9276	0.9325	12	21
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B35:17	HPPGPMPSV	0.9111	0.6662	9	18
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B35:30	HPPGPMPSV	0.9111	0.6662	9	18
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B35:23	HPPGPMPSV	0.9097	0.7228	9	18
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B35:24	GPMPSVGSM	0.8993	0.8338	12	21
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B35:17	GPMPSVGSM	0.8957	0.8347	12	21
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B35:30	GPMPSVGSM	0.8957	0.8347	12	21
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B15:39	FQGKLASFF	0.8535	0.9016	12	21
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B56:02	GPMPSVGSM	0.8517	0.6312	12	21
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B67:01	HPPGPMPSV	0.8396	0.9336	9	18
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B15:54	FQGKLASFF	0.8375	0.9208	12	21
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-C03:67	LFQGKLASF	0.8363	0.9834	11	20
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B55:04	GPMPSVGSM	0.7965	0.7214	12	21
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B35:09	GPMPSVGSM	0.7938	0.9693	12	21
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B35:22	GPMPSVGSM	0.7921	0.7481	12	21
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-C07:17	LFQGKLASF	0.7265	0.9807	11	20
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B67:01	GPMPSVGSM	0.7186	0.978	12	21
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-A69:01	HPPGPMPSV	0.6991	0.6087	9	18
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-A68:02	HPPGPMPSV	0.691	0.5108	9	18
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B15:20	FQGKLASFF	0.6482	0.9772	12	21
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B07:26	GPMPSVGSM	0.6313	0.5766	12	21
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B35:28	FQGKLASFF	0.5895	0.9779	12	21
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B56:05	GPMPSVGSM	0.5706	0.5671	12	21
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B48:02	FQGKLASFF	0.4394	0.9769	12	21
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B51:06	GPMPSVGSM	0.4047	0.6372	12	21
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B82:02	HPPGPMPSV	0.3749	0.5633	9	18
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B78:02	GPMPSVGSM	0.3505	0.9329	12	21
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B55:04	APGLFQGKL	0.3275	0.5655	8	17
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-C14:03	LFQGKLASF	0.3163	0.9842	11	20
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-C14:02	LFQGKLASF	0.3163	0.9842	11	20
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-C06:06	LFQGKLASF	0.3134	0.9928	11	20
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B67:01	APGLFQGKL	0.2254	0.9642	8	17
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-C01:02	HPPGPMPSV	0.0972	0.9624	9	18
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B35:43	GPMPSVGSM	0.0779	0.9127	12	21
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B15:08	GPMPSVGSM	0.0721	0.9112	12	21
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B82:02	GPMPSVGSM	0.0713	0.709	12	21
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B15:11	GPMPSVGSM	0.0601	0.9241	12	21
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-C01:03	HPPGPMPSV	0.048	0.9701	9	18
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B82:02	APGLFQGKL	0.0342	0.8802	8	17
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-C04:01	HPPGPMPSV	0.0089	0.9753	9	18
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B15:35	GLFQGKLASF	0.9999	0.9212	10	20
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B15:125	GLFQGKLASF	0.9999	0.903	10	20
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B15:27	GLFQGKLASF	0.9999	0.9201	10	20
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B15:50	GLFQGKLASF	0.9999	0.9633	10	20
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B15:24	GLFQGKLASF	0.9999	0.9297	10	20
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B15:33	GLFQGKLASF	0.9999	0.903	10	20
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B15:34	GLFQGKLASF	0.9999	0.903	10	20
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B15:135	GLFQGKLASF	0.9999	0.9155	10	20
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B15:12	GLFQGKLASF	0.9993	0.89	10	20
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B07:22	APPFHPPGPM	0.9977	0.619	5	15
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B07:09	APPFHPPGPM	0.9974	0.6301	5	15
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B38:05	FHPPGPMPSV	0.9966	0.9905	8	18
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B59:01	FHPPGPMPSV	0.9964	0.8702	8	18
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B15:73	GLFQGKLASF	0.9959	0.9841	10	20
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-A32:01	GLFQGKLASF	0.9915	0.9636	10	20
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B15:30	GLFQGKLASF	0.9913	0.9624	10	20
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B15:09	FHPPGPMPSV	0.9906	0.9379	8	18
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B15:39	GLFQGKLASF	0.9849	0.8445	10	20
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B39:11	FHPPGPMPSV	0.9471	0.9567	8	18
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B56:05	FHPPGPMPSV	0.9428	0.7955	8	18
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B78:02	FHPPGPMPSV	0.9352	0.947	8	18
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B51:21	FHPPGPMPSV	0.9291	0.8245	8	18
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B15:20	GLFQGKLASF	0.9033	0.9738	10	20
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B51:13	FHPPGPMPSV	0.9008	0.8783	8	18
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B51:09	FHPPGPMPSV	0.9002	0.7424	8	18
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B07:26	APPFHPPGPM	0.8972	0.5625	5	15
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B51:29	FHPPGPMPSV	0.8914	0.7332	8	18
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B51:14	FHPPGPMPSV	0.8682	0.7519	8	18
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-C07:04	FHPPGPMPSV	0.8401	0.9199	8	18
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B55:04	APPFHPPGPM	0.7955	0.7082	5	15
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B56:02	APPFHPPGPM	0.6612	0.748	5	15
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B67:01	APPFHPPGPM	0.629	0.9828	5	15
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B82:02	APPFHPPGPM	0.5814	0.7072	5	15
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B07:09	RAPPFHPPGPM	0.9995	0.7345	4	15
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B07:22	RAPPFHPPGPM	0.9995	0.7556	4	15
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-C01:02	RAPPFHPPGPM	0.9984	0.9702	4	15
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B07:26	RAPPFHPPGPM	0.9947	0.5704	4	15
GGT6-PELP1	chr17	4463676	chr17	4580107	200	HLA-B55:04	RAPPFHPPGPM	0.9847	0.5664	4	15

Top

Potential FusionNeoAntigen Information of GGT6-PELP1 in HLA II

Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).

Fusion gene

Hchr

Hbp

Tgene

Tchr

Tbp

HLA II

FusionNeoAntigen peptide

Neoantigen start (at BP 13)

Neoantigen end (at BP 13)

Top

Fusion breakpoint peptide structures of GGT6-PELP1

3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.

File name	BPseq	Hgene	Tgene	Hchr	Hbp	Tchr	Tbp	AAlen
6568	PEAPGLFQGKLASF	GGT6	PELP1	chr17	4463676	chr17	4580107	200

File name	BPseq	Hgene	Tgene	Hchr	Hbp	Tchr	Tbp	AAlen
6855	PPFHPPGPMPSVGS	GGT6	PELP1	chr17	4463676	chr17	4580107	200

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of GGT6-PELP1

Virtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.

HLA allele	PDB ID	File name	BPseq	Docking score	Glide score
HLA-B14:02	3BVN	6568	PEAPGLFQGKLASF	-7.15543	-7.26883
HLA-B14:02	3BVN	6568	PEAPGLFQGKLASF	-4.77435	-5.80965
HLA-B52:01	3W39	6568	PEAPGLFQGKLASF	-6.80875	-6.92215
HLA-B52:01	3W39	6568	PEAPGLFQGKLASF	-4.20386	-5.23916
HLA-A11:01	4UQ2	6568	PEAPGLFQGKLASF	-7.5194	-8.5547
HLA-A11:01	4UQ2	6568	PEAPGLFQGKLASF	-6.9601	-7.0735
HLA-A24:02	5HGA	6568	PEAPGLFQGKLASF	-7.52403	-7.63743
HLA-A24:02	5HGA	6568	PEAPGLFQGKLASF	-5.82433	-6.85963
HLA-B27:05	6PYJ	6568	PEAPGLFQGKLASF	-3.28285	-4.31815
HLA-B44:05	3DX8	6568	PEAPGLFQGKLASF	-5.91172	-6.94702
HLA-B44:05	3DX8	6568	PEAPGLFQGKLASF	-4.24346	-4.35686
HLA-B14:02	3BVN	6855	PPFHPPGPMPSVGS	-8.2662	-8.3796
HLA-B14:02	3BVN	6855	PPFHPPGPMPSVGS	-2.0165	-3.0518
HLA-B52:01	3W39	6855	PPFHPPGPMPSVGS	-5.20027	-6.23557
HLA-B52:01	3W39	6855	PPFHPPGPMPSVGS	-5.16522	-5.27862
HLA-A11:01	4UQ2	6855	PPFHPPGPMPSVGS	-7.50195	-8.53725
HLA-A24:02	5HGA	6855	PPFHPPGPMPSVGS	-6.45041	-7.48571
HLA-A24:02	5HGA	6855	PPFHPPGPMPSVGS	-6.16339	-6.27679
HLA-B27:05	6PYJ	6855	PPFHPPGPMPSVGS	-4.45967	-5.49497
HLA-B44:05	3DX8	6855	PPFHPPGPMPSVGS	-5.04436	-6.07966
HLA-B44:05	3DX8	6855	PPFHPPGPMPSVGS	-4.93981	-5.05321

Top

Vaccine Design for the FusionNeoAntigens of GGT6-PELP1

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.

Fusion gene	Hchr	Hbp	Tchr	Tbp	Start in +/-13AA	End in +/-13AA	FusionNeoAntigen peptide sequence	FusionNeoAntigen RNA sequence
GGT6-PELP1	chr17	4463676	chr17	4580107	10	20	GLFQGKLASF	CTCTTCCAGGGCAAGCTGGCCTCATTTTTT
GGT6-PELP1	chr17	4463676	chr17	4580107	10	21	GLFQGKLASFF	CTCTTCCAGGGCAAGCTGGCCTCATTTTTTCTG
GGT6-PELP1	chr17	4463676	chr17	4580107	11	20	LFQGKLASF	TTCCAGGGCAAGCTGGCCTCATTTTTT
GGT6-PELP1	chr17	4463676	chr17	4580107	12	21	FQGKLASFF	CAGGGCAAGCTGGCCTCATTTTTTCTG
GGT6-PELP1	chr17	4463676	chr17	4580107	12	21	GPMPSVGSM	CAGGGCAAGCTGGCCTCATTTTTTCTG
GGT6-PELP1	chr17	4463676	chr17	4580107	3	14	FRAPPFHPPGP	AAACCCCCGGAGGCACCAGGACTCTTCCAGGGC
GGT6-PELP1	chr17	4463676	chr17	4580107	4	15	RAPPFHPPGPM	CCCCCGGAGGCACCAGGACTCTTCCAGGGCAAG
GGT6-PELP1	chr17	4463676	chr17	4580107	5	15	APPFHPPGPM	CCGGAGGCACCAGGACTCTTCCAGGGCAAG
GGT6-PELP1	chr17	4463676	chr17	4580107	6	15	PPFHPPGPM	GAGGCACCAGGACTCTTCCAGGGCAAG
GGT6-PELP1	chr17	4463676	chr17	4580107	8	17	APGLFQGKL	CCAGGACTCTTCCAGGGCAAGCTGGCC
GGT6-PELP1	chr17	4463676	chr17	4580107	8	17	FHPPGPMPS	CCAGGACTCTTCCAGGGCAAGCTGGCC
GGT6-PELP1	chr17	4463676	chr17	4580107	8	18	FHPPGPMPSV	CCAGGACTCTTCCAGGGCAAGCTGGCCTCA
GGT6-PELP1	chr17	4463676	chr17	4580107	9	18	HPPGPMPSV	GGACTCTTCCAGGGCAAGCTGGCCTCA

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.

Fusion gene

Hchr

Hbp

Tchr

Tbp

Start in +/-13AA

End in +/-13AA

FusionNeoAntigen peptide

FusionNEoAntigen RNA sequence

Top

Information of the samples that have these potential fusion neoantigens of GGT6-PELP1

These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.

Cancer type	Fusion gene	Hchr	Hbp	Henst	Tchr	Tbp	Tenst	Sample
BRCA	GGT6-PELP1	chr17	4463676	ENST00000301395	chr17	4580107	ENST00000269230	TCGA-AN-A0FX
BRCA	GGT6-PELP1	chr17	4463676	ENST00000301395	chr17	4580107	ENST00000301396	TCGA-AN-A0FX

Top

Potential target of CAR-T therapy development for GGT6-PELP1

Predicted 3D structure. We used RoseTTAFold.

Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features

* Minus value of BPloci means that the break point is located before the CDS.

- In-frame and retained 'Transmembrane'.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Protein feature

Protein feature note

Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.

Hgene

Hchr

Hbp

Henst

Tgene

Tchr

Tbp

Tenst

DeepLoc result

Top

Related Drugs to GGT6-PELP1

Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Drug

Source

PMID

Top

Related Diseases to GGT6-PELP1

Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Disease

Source

PMID

Diseases associated with fusion partners.
(DisGeNet 4.0)

Partner

Gene

Disease ID

Disease name

# pubmeds

Source

	Fusion Gene and Fusion Protein Summary
	Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)
	Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)
	Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)
	Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)
	Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)
	Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)
	Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)
	Potential target of CAR-T therapy development
	Information on the samples that have these potential fusion neoantigens
	Fusion Protein Targeting Drugs - (Manual Curation)
	Fusion Protein Related diseases - (Manual Curation)